97 related articles for article (PubMed ID: 9680493)
1. Usefulness of markers of cell proliferation in the management of pituitary adenomas.
Losa M; Franzin A; Mortini P; Terreni MR; Mangili F; Giovanelli M
Clin Sci (Lond); 1998 Aug; 95(2):129-35. PubMed ID: 9680493
[TBL] [Abstract][Full Text] [Related]
2. Proliferation, bcl-2 expression and angiogenesis in pituitary adenomas: relationship to tumour behaviour.
Turner HE; Nagy Z; Gatter KC; Esiri MM; Wass JA; Harris AL
Br J Cancer; 2000 Apr; 82(8):1441-5. PubMed ID: 10780524
[TBL] [Abstract][Full Text] [Related]
3. Expression of cell proliferation markers in pituitary adenomas--correlation and clinical relevance of MIB-1 and anti-topoisomerase-IIalpha.
Wolfsberger S; Wunderer J; Zachenhofer I; Czech T; Böcher-Schwarz HG; Hainfellner J; Knosp E
Acta Neurochir (Wien); 2004 Aug; 146(8):831-9. PubMed ID: 15254805
[TBL] [Abstract][Full Text] [Related]
4. Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.
Filippella M; Galland F; Kujas M; Young J; Faggiano A; Lombardi G; Colao A; Meduri G; Chanson P
Clin Endocrinol (Oxf); 2006 Oct; 65(4):536-43. PubMed ID: 16984249
[TBL] [Abstract][Full Text] [Related]
5. Clinical tumor growth and comparison with proliferation markers in non-functioning (inactive) pituitary adenomas.
Saeger W; Lüdecke B; Lüdecke DK
Exp Clin Endocrinol Diabetes; 2008 Feb; 116(2):80-5. PubMed ID: 18072009
[TBL] [Abstract][Full Text] [Related]
6. Pathobiology of pituitary adenomas and carcinomas.
Scheithauer BW; Gaffey TA; Lloyd RV; Sebo TJ; Kovacs KT; Horvath E; Yapicier O; Young WF; Meyer FB; Kuroki T; Riehle DL; Laws ER
Neurosurgery; 2006 Aug; 59(2):341-53; discussion 341-53. PubMed ID: 16883174
[TBL] [Abstract][Full Text] [Related]
7. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
[TBL] [Abstract][Full Text] [Related]
8. Proliferation index of nonfunctioning pituitary adenomas: correlations with clinical characteristics and long-term follow-up results.
Losa M; Franzin A; Mangili F; Terreni MR; Barzaghi R; Veglia F; Mortini P; Giovanelli M
Neurosurgery; 2000 Dec; 47(6):1313-8; discussion 1318-9. PubMed ID: 11126902
[TBL] [Abstract][Full Text] [Related]
9. [Pituitary adenomas: relationship between invasiveness and proliferative cell nuclear index].
Tella Junior OI; Herculano MA; Delcelo R
Arq Neuropsiquiatr; 2000 Dec; 58(4):1055-63. PubMed ID: 11105073
[TBL] [Abstract][Full Text] [Related]
10. Multiregional sampling reveals a homogenous distribution of Ki-67 proliferation rate in pituitary adenomas.
Wolfsberger S; Kitz K; Wunderer J; Czech T; Boecher-Schwarz HG; Hainfellner JA; Knosp E
Acta Neurochir (Wien); 2004 Dec; 146(12):1323-7; discussion 1327-8. PubMed ID: 15480830
[TBL] [Abstract][Full Text] [Related]
11. Transsphenoidal adenomectomy for GH-, PRL- and ACTH-secreting pituitary tumours: outcome analysis in a series of 125 patients.
Esposito V; Santoro A; Minniti G; Salvati M; Innocenzi G; Lanzetta G; Cantore G
Neurol Sci; 2004 Dec; 25(5):251-6. PubMed ID: 15624082
[TBL] [Abstract][Full Text] [Related]
12. Endocrinological outcome following first time transsphenoidal surgery for GH-, ACTH-, and PRL-secreting pituitary adenomas.
Kristof RA; Schramm J; Redel L; Neuloh G; Wichers M; Klingmüller D
Acta Neurochir (Wien); 2002 Jun; 144(6):555-61; discussion 561. PubMed ID: 12111488
[TBL] [Abstract][Full Text] [Related]
13. Pituitary adenoma: a DNA flow cytometric study of 192 clinicopathologically characterized tumors.
Gaffey TA; Scheithauer BW; Leech RW; Blick K; Kovacs K; Horvath E; Weaver AL; Lloyd RV; Ebersold M; Laws ER; DeBault LE
Clin Neuropathol; 2005; 24(2):56-63. PubMed ID: 15803804
[TBL] [Abstract][Full Text] [Related]
14. The expression of ghrelin in somatotroph and other types of pituitary adenomas.
Wasko R; Jaskula M; Kotwicka M; Andrusiewicz M; Jankowska A; Liebert W; Sowinski J
Neuro Endocrinol Lett; 2008 Dec; 29(6):929-38. PubMed ID: 19112387
[TBL] [Abstract][Full Text] [Related]
15. Indices of apoptosis and proliferation as potential prognostic markers in non-functioning pituitary adenomas.
Ibrahim AE; Pickering RM; Gawne-Cain ML; King S; Lees PD; Ellison DW
Clin Neuropathol; 2004; 23(1):8-15. PubMed ID: 14986928
[TBL] [Abstract][Full Text] [Related]
16. Fractionated stereotactic conformal radiotherapy for secreting and nonsecreting pituitary adenomas.
Minniti G; Traish D; Ashley S; Gonsalves A; Brada M
Clin Endocrinol (Oxf); 2006 May; 64(5):542-8. PubMed ID: 16649974
[TBL] [Abstract][Full Text] [Related]
17. Pure endoscopic endonasal approach for pituitary adenomas: early surgical results in 200 patients and comparison with previous microsurgical series.
Dehdashti AR; Ganna A; Karabatsou K; Gentili F
Neurosurgery; 2008 May; 62(5):1006-15; discussion 1015-7. PubMed ID: 18580798
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical analysis of RCAS1 in human pituitary adenomas.
Umeoka K; Sanno N; Oyama K; Tahara S; Kurotani R; Ikuyama S; Nakashima M; Watanabe T; Osamura RY; Teramoto A
Mod Pathol; 2001 Dec; 14(12):1232-6. PubMed ID: 11743045
[TBL] [Abstract][Full Text] [Related]
19. Endoscopic transsphenoidal treatment in recurrent and residual pituitary adenomas--first experience.
Rudnik A; Zawadzki T; Gałuszka-Ignasiak B; Bazowski P; Duda I; Wojtacha M; Rudnik AI; Krawczyk I
Minim Invasive Neurosurg; 2006 Feb; 49(1):10-4. PubMed ID: 16547875
[TBL] [Abstract][Full Text] [Related]
20. [The natural course of non-functioning pituitary adenomas].
Wolffenbuttel BH; van den Berg G; Hoving EW; van der Klauw MM
Ned Tijdschr Geneeskd; 2008 Nov; 152(47):2537-43. PubMed ID: 19174932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]